

Summary of status of development and availability of A/Perth/16/2009 (H3N2)-like candidate vaccine viruses* and potency testing reagents

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System. National or Regional control authorities approve the composition and formulation of vaccines used in each country

11 August 2011

Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
*A/Perth/10/2010 (H3N2)		CDC, USA		
	NYMC X-207	Classical	New York Medical College, USA	NYMC, USA
A/Perth/16/2009 (H3N2)		WHO CCs NIBSC, UK		
	NIB-64	Classical	NIBSC, UK	NIBSC, UK NIID, Japan
A/Brisbane/11/ 2010 (H3N2)		WHO CCs		
	NYMC X-197	classical	New York Medical College, USA	New York Medical College, USA
A/Hawai/07/2009 (H3N2)		WHO CCs		
	CDCID-RG23	Reverse Genetics	CDC, USA	CDC, USA
A/Wisconsin/15/2009 (H3N2)		WHO CCs NIBSC, UK		
	NYMC X-183	Classical	New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
	CDCID-RG24	Reverse Genetics	CDC, USA	CDC, USA
		WHO CCs		
A/Guangdong- Luohu/1256/2009 (H3N2)	NYMC X-185	Classical	New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
	NYMC X-185xp			NYMC, USA NIID, Japan
A/Hong Kong/ 26560/2009 (H3N2)	Wild type virus			WHO CCs
	NYMC X-189	Classical	New York Medical College, USA	NYMC, USA

^{*}new candidate vaccine virus

Parent virus	Candidate vaccine virus	Type of virus or reassortant		oping institute	Available from
	Wild type virus			WHO CCs NIBSC, UK	
A/Victoria/210/2009 (H3N2)	IVR-155			CSL, Australia	NIBSC, UK NIID, Japan
	NYMC X-18	7 Clas	sical	New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
	NIB-65		NIBSC, UK		NIBSC, UK
	Wild type virus				WHO CCs
A/Philippines/2191/2009 (H3N2)	NYMC X-19	1 Cla	ssical	New York Medical College, USA	NYMC, USA

Institutes contact details for candidate vaccine viruses orders/information:

CDC: rdonis@cdc.gov

NIBSC: <u>standards@nibsc.hpa.org.uk</u> or <u>enquiries@nibsc.hpa.org.uk</u>

NIID: <u>sitamura@nih.go.jp</u>
NYMC: <u>doris_bucher@nymc.edu</u>

Reference antigens (freeze-dried)

	Starting materials				
Parent virus	cvv	egg or Cell	Ref Ag Lot #	Unitage (µgHA/mL)	Available from
A/Wisconsin/15/2009	NYMC X-183		2009/86B	75	
			2010/87B	71	TGA
			09/310	48	NIBSC
A/Victoria/210/2009		Egg	10/102	26	NIBSC
	NYMC X-187		70	71	CBER/FDA
			H3-Ag-1003	72	CBER/FDA
			2010AH3B	71	NIID

Sheep antisera

Purified HA from		Order		
Parent virus	Egg or Cell	/ Lot #	Available from	
A/Perth/16/2009		10/182	NIBSC	
A/Singapore/37/2009	Egg	AS400	TGA	
A/Wisconsin/15/2009		H3-Ab-1005	CBER/FDA	

The above-listed potency testing reagents have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagents orders/information:

NIBSC: <u>standards@nibsc.hpa.org.uk</u>
TGA: <u>influenza.standards@tga.gov.au</u>

NIID: <u>sitamura@nih.go.jp</u>

CBER/FDA: Rajesh.Gupta@fda.hhs.gov

For general enquiries, please contact GISN@who.int

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/en/